The Online Investor
Drugs & Pharmaceuticals M&A image Drugs & Pharmaceuticals M&A » By The Online Investor Staff, updated Thu., Aug. 18, 7:10 AM Recent mergers and acquisitions in the Drugs & Pharmaceuticals M&A category.

Slide #25. Cumberland Pharmaceuticals Vaprisol from Astellas Pharma US, Inc.

Acquirer: Cumberland Pharmaceuticals (NASDAQ:CPIX)
Acquiree: Vaprisol from Astellas Pharma US, Inc.
Details: Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) today announced the acquisition of Vaprisol from Astellas Pharma US, Inc.

Cumberland Pharmaceuticals is a pharmaceutical company engaged on the acquisition, development and commercialization of prescription products. Co.'s portfolio of brands include: Acetadote® (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolor® (ibuprofen) injection, for the treatment of pain and fever; Kristalose® (lactulose) for the treatment of constipation; Omeclamox®-Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori infection and related duodenal ulcer disease; and Vaprisol® (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia.

Open the CPIX Page at The Online Investor »

Company Name: 
Cumberland Pharmaceuticals Inc
Website: 
www.cumberlandpharma.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding CPIX: 
4
Total Market Value Held by ETFs: 
$2.30B
Total Market Capitalization: 
$34.00M
% of Market Cap. Held by ETFs: 
6777.36%
 

Open the CPIX Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree CPIX Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Strong Buy (4.00 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)

Analysts' Target Price:
CPIX Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Drugs & Pharmaceuticals M&A - Slide 25 of 100 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.